ResearcherSapporo Medical UniversityNo recent work listed
Hiroaki Shima
Matched on ORCID iD 0000-0003-4413-2008; OpenAlex author ID A5083993923. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper
Papers 4
- Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma. Co-author DOI 10.1111/cas.14106↗
- Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine. Co-author DOI 10.1007/s00262-018-2217-x↗
- Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis? Co-author DOI 10.1007/s00595-015-1120-8↗
- Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Co-author DOI 10.1111/cas.12046↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yoshihiko Hirohashi · 4 shared papers, 2013–2019 · strength 0.21
- Paper Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcino… DOI 10.1111/cas.14106↗
- Paper Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine. DOI 10.1007/s00262-018-2217-x↗
- Paper Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis? DOI 10.1007/s00595-015-1120-8↗
- Yasutoshi Kimura · 4 shared papers, 2013–2019 · strength 0.21
- Paper Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcino… DOI 10.1111/cas.14106↗
- Paper Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine. DOI 10.1007/s00262-018-2217-x↗
- Paper Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis? DOI 10.1007/s00595-015-1120-8↗
- Toshihiko Torigoe · 4 shared papers, 2013–2019 · strength 0.21
- Paper Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcino… DOI 10.1111/cas.14106↗
- Paper Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine. DOI 10.1007/s00262-018-2217-x↗
- Paper Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis? DOI 10.1007/s00595-015-1120-8↗
- Toru Mizuguchi · 3 shared papers, 2016–2019 · strength 0.18
- Paper Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcino… DOI 10.1111/cas.14106↗
- Paper Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine. DOI 10.1007/s00262-018-2217-x↗
- Paper Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis? DOI 10.1007/s00595-015-1120-8↗
- Koichi Hirata · 3 shared papers, 2013–2019 · strength 0.14
- Paper Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcino… DOI 10.1111/cas.14106↗
- Paper Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis? DOI 10.1007/s00595-015-1120-8↗
- Paper Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic canc… DOI 10.1111/cas.12046↗
- Ichiro Takemasa · 2 shared papers, 2018–2019 · strength 0.13
- Hidekazu Kameshima · 2 shared papers, 2013–2018 · strength 0.09
- Masafumi Imamura · 2 shared papers, 2013–2018 · strength 0.09
- Kohzoh Imai · 1 shared paper, 2019 · strength 0.07
- Satoshi Wada · 1 shared paper, 2019 · strength 0.07
- Atsushi Miyamoto · 1 shared paper, 2016 · strength 0.05
- Yasuaki Tamura · 1 shared paper, 2013 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.